$BioCryst制药 (BCRX.US)$BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
BioCryst制药股票讨论
biocryst制药 | SC 13G/A: 个人取得所有权的声明 (修正)- 先锋集团(9.81%)
Larger Image: tradingview.com...
$BioCryst制药 (BCRX.US)$
Benzinga· 3分钟前
BioCryst制药公司（Nasdaq：BCRX）今天宣布了有关口服一次日服用的ORLADEYO（berotralstat）的新实证，证明了美国患有遗传性血管性水肿（HAE）的患者在卫生资源利用方面（HRU）出现显著减少，包括显著减少...
只需要买进日元，持有日元，便可在日元中获得价值。
美国政府向BioCryst授予6900万美元的Rapivab®（Peramivir注射剂）合同，用于战略性国家储备。
杰富瑞分析师列举了10种可能的政策，特朗普的支持者非常看好这些政策，同时认为这些政策对制造业-半导体、金属期货和能源行业的股票有利。
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
暂无评论